This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -108.70% and 6.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
by Zacks Equity Research
Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
by Zacks Equity Research
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.
Is Ardelyx (ARDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.
BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 7.94% and 5.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -1.72% and 19.80%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 10.53% and 8.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 11.76% and 0.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Agile Therapeutics (AGRX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 5.26% and -13.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Agile Therapeutics (AGRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 4.76% and -18.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Agile Therapeutics (AGRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 9.09% and -82.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 13.04% and -25.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
How Agile Therapeutics (AGRX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Agile Therapeutics (AGRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is the Options Market Predicting a Spike in Agile Therapeutics (AGRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
Agile Therapeutics (AGRX) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Agile Therapeutics (AGRX) closed at $1.86 in the latest trading session, marking no change from the prior day.
Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
Buy Multibagger Stocks as Odds of a Rally Are High in 2020
by Tirthankar Chakraborty
Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.
The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold
Here's How to Play Stocks as US-Iran Tensions Mount
by Tirthankar Chakraborty
Since we do expect at least short-term volatility, low-beta stocks are the best choice as they are less correlated to the index and thus tend to be less volatile.
Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
Is Agile Therapeutics (AGRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGRX) Outperforming Other Medical Stocks This Year?